

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

VOLUNTARY ANNOUNCEMENT PRESENTATION OF INITIAL FOLLOW-UP FINDINGS OF BORON NEUTRON CAPTURE THERAPY AT THE 22ND CONGRESS ON NEUTRON CAPTURE THERAPY

This voluntary announcement is made by China Biotech Services Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) to inform shareholders of the Company and potential investors of the latest business development of the Group.

The board of directors (the “Director(s)”) of the Company (the “Board”) is pleased to announce that, at the 22nd Congress on Neutron Capture Therapy (JSNCT22) held at Kyoto University, Japan, Pengbo (Hainan) Medical Technology Co., Ltd., a subsidiary of the Company, announced verbally the clinical real-world data from the first 10 patients with head and neck cancers who received the boron neutron capture therapy (“BNCT”) in Pengbo (Hainan) BNCT hospital (the “Pengbo Hainan Hospital”), based on a three-month (90-day) follow-up after treatment.

It is shown in the findings that, among the first 10 evaluable patients, 8 cases were confirmed as effective treatment during their three-month (90-day) post-treatment follow-up. Among these, the complete remission rate (i.e. complete disappearance of target tumors, no new lesions and normalization of relevant clinical indicators) was 40% (4 out of 10 cases); and the partial remission rate (i.e. a reduction of 30% or more in the sum of the longest diameters of target lesions and no new lesions) was 40% (4 out of 10 cases), demonstrating significant clinical efficacy.

The Pengbo Hainan Hospital, the Group's flagship project located in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the PRC, commenced trial operations in February 2026, and began patient treatment for the first time in March 2026 with dozens of treatments completed to date. Leveraging the policy advantages of the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, the Group has introduced NeuCure® neutron irradiation system, the first globally approved BNCT system, and Steboronine®, the first globally approved BNCT drug, to provide safe and precise BNCT services to cancer patients.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 3 August 2026

As at the date of this announcement, the Board comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.